The effects of Taurine supplementation on inflammatory markers and clinical outcomes in patients with traumatic brain injury: a double-blind randomized controlled trial

Table 3 The clinical outcomes of study participants

Variable	Taurine (n = 16)	Control (n = 16)	p-value^*
APACHEII score
Day 1	14 (12, 17)	13 (11, 15)	0.34
Day 14	12 (9, 13)	13 (9, 14)	0.31
Changes (1, 14)	−4 (−6, −1)	−1 (− 4, 2)	0.05
p-value^¥	0.003	0.32
SOFA score
Day 1	8 (6, 9)	8 (6, 9)	0.56
Day 14	5 (4, 6)	7 (5, 8)	0.02
Changes (1, 14)	−3 (−4, −1)	−1 (−3, 1)	0.06
p-value^¥	0.003	0.06
GCS
Day 1	7 (7, 7)	7 (7, 8)	0.18
Day 14	9 (7, 10)	8 (6, 9)	0.17
Changes (1, 14)	2 (0, 3)	0.0 (−1, 1)	0.03
p-value^¥	0.002	0.30
30-day Mortality (N (%))			0.33
Yes	1 (6.3)	4 (25)
No	15 (93.8)	12 (75)
Days on mechanical ventilation	18 ± 9	23 ± 14	0.26
Length of ICU stay	22 (17, 31)	21 (18, 39)	0.96

Values are presented as mean ± SD, median (IQR) or Frequency (percent). Independent Samples T test was used for days on mechanical ventilation, Fisher’s exact test for 30-day mortality and Mann-Whitney U test for others. Within group comparison was made by by Wilcoxon for APACHEII and SOFA scores and GCS. *p-value for comparison between group; ^¥ p-value for comparison within group.

ISSN: 1475-2891